Live
FierceBiotechNovartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4BLabiotechHow Daiichi Sankyo aims to become a top five oncology player by 2035PharmaVoiceAmid a flurry of biotech deals, China looks to keep innovation at homeCellPrion-based protein self-assembly tunes mutagenesis to enable rapid adaptationEndpoints NewsEthyreal lands $101M to treat both Graves' and thyroid eye diseaseEndpoints NewsSanofi to mull riliprubart’s future after stopping late-stage nerve disease studyFierceBiotechCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechsFierceBiotechSanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continueLabiotechBeyond amyloid and dopamine: emerging technologies reshaping neurologyEndpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drugeLifeAltered cognitive processes shape tactile perception in autismeLifeCell size modulates ferroptosis susceptibility
BioWorld 5 janv. 2026

Psithera spun out of Roivant with $47.5M and immune, inflammatory focus

Psithera spun out of Roivant with $47.5M and immune, inflammatory focus

Original
Contenu indisponible. Consultez la source originale.